Qiagen NV (NYSE:QGEN) Position Trimmed by Hardman Johnston Global Advisors LLC

Share on StockTwits

Hardman Johnston Global Advisors LLC cut its stake in Qiagen NV (NYSE:QGEN) by 2.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,219,305 shares of the company’s stock after selling 93,467 shares during the quarter. Qiagen makes up approximately 7.6% of Hardman Johnston Global Advisors LLC’s portfolio, making the stock its 4th largest holding. Hardman Johnston Global Advisors LLC owned approximately 1.87% of Qiagen worth $171,093,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. O Shaughnessy Asset Management LLC purchased a new position in Qiagen in the 1st quarter worth approximately $30,000. Cornerstone Advisors Inc. purchased a new stake in shares of Qiagen during the 1st quarter valued at approximately $44,000. Bessemer Group Inc. raised its position in shares of Qiagen by 5,918.5% during the 2nd quarter. Bessemer Group Inc. now owns 1,625 shares of the company’s stock valued at $66,000 after buying an additional 1,598 shares during the period. Rockefeller Capital Management L.P. raised its position in shares of Qiagen by 83.1% during the 1st quarter. Rockefeller Capital Management L.P. now owns 2,113 shares of the company’s stock valued at $86,000 after buying an additional 959 shares during the period. Finally, Marshall Wace North America L.P. purchased a new stake in shares of Qiagen during the 1st quarter valued at approximately $89,000. 65.04% of the stock is currently owned by institutional investors and hedge funds.

Qiagen stock traded down $0.62 during trading on Tuesday, hitting $34.19. The company had a trading volume of 289,368 shares, compared to its average volume of 883,349. Qiagen NV has a 1-year low of $32.33 and a 1-year high of $41.55. The company has a current ratio of 1.77, a quick ratio of 1.59 and a debt-to-equity ratio of 0.54. The company’s 50 day simple moving average is $38.21 and its 200-day simple moving average is $38.76. The stock has a market cap of $7.80 billion, a price-to-earnings ratio of 25.51, a price-to-earnings-growth ratio of 2.12 and a beta of 0.83.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, July 24th. The company reported $0.33 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.34 by ($0.01). Qiagen had a net margin of 12.94% and a return on equity of 12.10%. The company had revenue of $381.60 million during the quarter, compared to analyst estimates of $386.37 million. During the same quarter last year, the business posted $0.33 EPS. The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. As a group, analysts forecast that Qiagen NV will post 1.41 earnings per share for the current fiscal year.

Several analysts have recently commented on QGEN shares. Exane BNP Paribas raised shares of Qiagen from a “neutral” rating to an “outperform” rating in a research report on Friday, July 12th. Goldman Sachs Group reaffirmed a “buy” rating on shares of Qiagen in a research report on Thursday, August 1st. Barclays lifted their price target on shares of Qiagen from $43.00 to $45.00 and gave the company an “overweight” rating in a research report on Friday, June 21st. ValuEngine lowered shares of Qiagen from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Zacks Investment Research lowered shares of Qiagen from a “hold” rating to a “sell” rating and set a $38.00 price target on the stock. in a research report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $41.67.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Recommended Story: What is a growth and income fund?

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NYSE:QGEN).

Institutional Ownership by Quarter for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.